RNA-based
vaccines against
SARS-CoV-2 are critical to limiting COVID-19 severity and spread. Cellular mechanisms driving
antigen-specific responses to these
vaccines, however, remain uncertain. We used single-
cell technologies to identify and characterized
antigen-specific
cells and
antibody responses to the
RNA vaccine BNT162b2 in longitudinal samples from a cohort of healthy
donors. Mass cytometry and
machine learning pinpointed a novel expanding,
population of
antigen-specific non-canonical
memory CD4+ and CD8+
T cells.
B cell sequencing suggested progression from
IgM, with apparent cross-reactivity to endemic
coronaviruses, to
SARS-CoV-2-specific
IgA and
IgG memory B cells and plasmablasts. Responding
lymphocyte populations correlated with eventual
SARS-CoV-2 IgG and a
donor lacking these
cell populations failed to sustain
SARS-CoV-2-specific
antibodies and experienced breakthrough
infection. These integrated proteomic and genomic platforms reveal an
antigen-specific cellular basis of
RNA vaccine-based
immunity. ONE SENTENCE SUMMARYSingle-
cell profiling reveals the cellular basis of the
antigen-specific response to the BNT162b2
SARS-CoV-2 RNA vaccine.